Natera(NTRA) - 2024 Q4 - Annual Report

Revenue and Financial Performance - A significant portion of the company's revenues is expected to come from sales of Panorama, Horizon, and Signatera[15] - Product revenues for the year ended December 31, 2024, reached $1,685.1 million, a 57.5$1,068.5 million in 2023[502] - Total revenues for 2024 were $1,696.9 million, up 56.8$1,082.6 million in 2023[502] - The net loss for 2024 was $190.4 million, a significant improvement compared to a net loss of$434.8 million in 2023[502] - Cash, cash equivalents, and restricted cash increased to $945.6 million in 2024 from$642.1 million in 2023, reflecting a 47.3% growth[500] - Total assets grew to $1,660.7 million in 2024, up from$1,441.7 million in 2023, marking a 15.2% increase[500] - Total stockholders' equity increased to $1,195.4 million in 2024, compared to$765.3 million in 2023, reflecting a 56.3% growth[500] - The company generated net cash provided by operating activities of $135.7 million in 2024, a turnaround from net cash used of$247.0 million in 2023[514] - Revenue from insurance carriers was $1,571.8 million in 2024, up from$954.2 million in 2023, and $690.8 million in 2022, indicating strong growth in this segment[614] - Total revenues for the year ended December 31, 2024, reached$1,696.9 million, a significant increase from $1,082.6 million in 2023, and$820.2 million in 2022[614] Expenses and Losses - The company has incurred net losses since inception and expects to continue incurring losses for the foreseeable future[21] - Research and development expenses rose to $404.1 million in 2024, compared to$320.7 million in 2023, indicating a 26.0% increase[502] - Selling, general, and administrative expenses increased to $841.3 million in 2024, up from$618.3 million in 2023, a rise of 36.1%[502] - The company reported a basic and diluted net loss per share of $1.53 for 2024, improving from a loss of$3.78 per share in 2023[502] - The company has an accumulated deficit of $2.6 billion as of December 31, 2024, indicating ongoing financial challenges despite recent improvements[514] - The company reported stock-based compensation expenses of$274.4 million in 2024, up from $191.8 million in 2023[514] Debt and Financial Instruments - The company’s gross debt outstanding on its Credit Line is$80.4 million, with an interest rate that could increase annual interest expense by $0.8 million for a 100 basis point change[483] - An incremental change in the investment yield of 100 basis points would increase annual interest income by approximately$0.2 million[483] - The estimated fair value of the total principal outstanding and accrued interest of the Credit Line was $80.4 million as of December 31, 2024[622] - The company had$20.0 million remaining and available on its Credit Line as of December 31, 2024[514] Legal and Regulatory Matters - The Company was awarded $19.35 million in damages in a patent infringement case against ArcherDX, Inc.[655] - The jury awarded damages totaling$96.3 million to the Company in a patent litigation case against CareDx, Inc.[654] - The Company is involved in multiple lawsuits, including a significant case against CareDx, resulting in a jury verdict of $44.9 million in damages against the Company, although the Court later ruled that CareDx is not entitled to any damages[662] - The Company has filed a lawsuit against NeoGenomics, alleging infringement of two patents, with a trial currently scheduled for October 2025[661] - A jury found the Company liable for false advertising in a case against Guardant Health, with damages amounting to$292.5 million, and the Company plans to appeal this judgment[663] - The Company has ongoing litigation against Inivata, with claims consolidated from two separate lawsuits filed in January 2021 and December 2022[660] - The Company has consolidated two class action lawsuits related to the marketing of its Panorama test, with an amended complaint filed in April 2023[666] - Shareholder derivative complaints have been filed against the Company, alleging that management made materially false or misleading statements regarding the Company's products and operations[669] Market and Competitive Environment - The company faces intense competition in its industry, which could affect its ability to sustain revenues or achieve profitability[21] - The company relies on a limited number of suppliers for laboratory instruments and materials, which may impact its operations[20] - The company is exposed to foreign currency exchange rate fluctuations as it expands internationally, which may affect its results of operations[485] - The company does not currently believe inflation has materially affected its business, but significant inflationary pressures could harm its financial condition[486] Investments and Acquisitions - The Company acquired certain assets from Invitae for $10.5 million, with an additional payment of up to$42.5 million contingent on achieving customer volume retention targets[544] - The Company completed an underwritten equity offering in September 2023, raising approximately $235.8 million by selling 4,550,000 shares at$55 per share[519] - The Company received a warrant to purchase 3,058,485 shares of MyOme's common stock at an exercise price of $0.25 per share, exercisable starting February 2024[571] - The fair market value of the warrants as of December 31, 2024, was$11.2 million, compared to $1.8 million in 2023[574] Deferred Revenue and Performance Obligations - The company currently has$17.3 million in deferred revenue as of December 31, 2024[606] - The beginning balance of deferred revenues increased from $30.8 million in 2023 to$35.7 million in 2024, with an ending balance of $36.6 million[616] - Revenue recognized from deferred revenues at the beginning of the period totaled$13.7 million, with $10.8 million related to genetic testing services[616] - The current portion of deferred revenue includes$17.6 million from genetic testing services, $1.7 million from Foundation Medicine, and$0.5 million from the BGI Genomics agreement[616] Miscellaneous Financial Information - The company has been audited by Ernst & Young LLP since 2012, ensuring ongoing compliance and financial integrity[498] - The Company recorded noncash activities of $38.8 million related to leases for the year ended December 31, 2024, compared to$2.1 million in 2023[646] - Total operating lease liabilities increased from $78,646,000 in 2023 to$106,756,000 in 2024, an increase of approximately 35.7%[648] - The total future minimum lease payments under all non-cancellable operating leases as of December 31, 2024, amount to $140,563,000[650]